Edition:
United States

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

6.97USD
20 Apr 2018
Change (% chg)

$0.02 (+0.29%)
Prev Close
$6.95
Open
$6.91
Day's High
$7.03
Day's Low
$6.88
Volume
174,833
Avg. Vol
434,626
52-wk High
$8.09
52-wk Low
$1.42

Select another date:

Tue, Mar 27 2018

BRIEF-Arrowhead Pharmaceuticals Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV

* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Arrowhead Begins Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD BEGINS DOSING IN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE

BRIEF-Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT

* ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B Source text for Eikon: Further company coverage:

BRIEF-Arrowhead Pharmaceuticals Reports Fiscal 2018 Q1 Results

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 FIRST QUARTER RESULTS

BRIEF-Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arrowhead Pharma Announces Proposed Underwritten Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Silence Therapeutics ‍Sells Further Stake In Arrowhead Pharmaceuticals ​

* ‍SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.​

BRIEF-Arrowhead Pharmaceuticals Files For Regulatory Clearance To Begin Phase 1/2 Study Of ARO-HBV

* ARROWHEAD PHARMACEUTICALS FILES FOR REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV Source text for Eikon: Further company coverage:

Select another date: